Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants
Tatsuhiko Ozawa, Hideki Tani, Yuki Anraku, Shunsuke Kita, Emiko Igarashi, Yumiko Saga, Noriko Inasaki, Hitoshi Kawasuji, Hiroshi Yamada, Soichiro Sasaki, Mayu Somekawa, Jiei Sasaki, Yoshihiro Hayakawa, Yoshihiro Yamamoto, Yoshitomo Morinaga, Nobuyuki Kurosawa, Masaharu Isobe, Hideo Fukuhara, Katsumi Maenaka, Takao Hashiguchi, Hiroyuki Kishi, Isao Kitajima, Shigeru Saito, Hideki Niimi
Abstract
prophylactic treatment, and the reactivity to the Omicron strain was reduced. The structural analyses revealed that antibody UT28K Fab and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. In addition, a mutation analysis suggested that the emergence of a UT28K neutralization-resistant SARS-CoV-2 variant was unlikely, as this variant would likely lose its competitive advantage over circulating SARS-CoV-2. Our data suggest that UT28K offers potent protection against SARS-CoV-2, including newly emerging variants.